HISUN(SH:600267)2016-04-28 16:00Financial Performance - Operating revenue for the period was CNY 2,381,670,475.84, reflecting a growth of 1.10% year-on-year[6] - Net profit attributable to shareholders decreased by 91.45% to CNY 561,346.62 compared to the same period last year[6] - Basic earnings per share increased by 20.00% to CNY 0.006[6] - The company reported a net profit of CNY 5,544,897.26 from non-recurring gains and losses[9] - The company reported a net profit of CNY 1,388,551,593.22 for the period, compared to CNY 1,379,177,500.07 in the previous year, indicating a growth of about 0.5%[24] - Net profit for Q1 2016 reached ¥42,651,367.63, up from ¥41,678,036.99, representing a year-on-year increase of 2.3%[25] - The company reported a total comprehensive income of ¥42,766,278.14 for Q1 2016, compared to ¥41,540,932.60 in the same quarter last year, reflecting a growth of 2.9%[25] Assets and Liabilities - Total assets increased by 6.80% to CNY 20,478,984,301.08 compared to the end of the previous year[6] - The total assets of the company reached RMB 20,478,984,301.08, up from RMB 19,174,426,311.14, indicating overall growth[19] - The total assets as of March 31, 2016, amounted to CNY 11,886,971,974.92, compared to CNY 10,692,736,083.67 at the beginning of the year, showing an increase of approximately 11.1%[23] - Total liabilities as of March 31, 2016, were CNY 5,521,871,964.67, up from CNY 4,337,010,166.57 at the start of the year, representing a growth of about 27.4%[24] Cash Flow - Cash flow from operating activities dropped significantly by 87.72% to CNY 20,101,889.75[6] - The net cash flow from operating activities was ¥20,101,889.75, significantly down from ¥163,749,236.25 in the previous year, indicating a decline of 87.7%[29] - Cash and cash equivalents increased to CNY 1,652,819,007.30 from CNY 826,607,571.30, marking a significant rise of approximately 100.0%[22] - Cash and cash equivalents at the end of Q1 2016 increased to ¥3,202,905,242.29 from ¥2,077,625,360.01, marking a rise of 54.2%[30] - The total cash and cash equivalents at the end of the period reached $1.65 billion, an increase from $650.45 million in the previous period[33] Shareholder Information - The number of shareholders reached 30,035 by the end of the reporting period[10] - The largest shareholder, Zhejiang Haizheng Group Co., Ltd., holds 33.22% of the shares[10] Financial Adjustments and Strategies - The company plans to transfer 14% of its stake in Zhejiang Yunkai Yamei Pharmaceutical Technology Co., Ltd. as part of its strategic adjustments[15] - The company has applied for financial assistance from its controlling shareholder, with a total amount not exceeding RMB 400 million, of which RMB 245 million remains unpaid[13] - The company is actively pursuing a collaboration with Sanofi in the diabetes treatment field, currently in the due diligence phase[14] Operational Costs and Expenses - Total operating costs for Q1 2016 were CNY 2,318,471,426.99, compared to CNY 2,290,953,546.11 in the previous year, reflecting an increase of about 1.2%[24] - Operating expenses decreased, with sales expenses at ¥59,809,901.55, down 10.5% from ¥66,881,764.30 in the previous year[28] - The company reported an increase in investment income to ¥11,017,051.82, up from ¥8,603,181.63, indicating a growth of 28.8%[28] Financial Ratios - The weighted average return on equity increased by 0.016 percentage points to 0.088%[6] Other Financial Metrics - The company's cash and cash equivalents increased by 44.38% to RMB 3,268,592,850.39 from RMB 2,263,811,807.18 due to the issuance of corporate bonds[13] - Prepayments rose by 97.56% to RMB 66,807,685.47 from RMB 33,816,150.06, primarily due to an increase in pre-sale payments received[13] - The company's financial expenses increased by 62.52% to RMB 52,307,499.62 from RMB 32,185,217.63, attributed to the issuance of corporate bonds and the capitalization of certain borrowings being discontinued[13] - The asset impairment loss surged by 428.59% to RMB 30,501,506.98 from RMB 5,770,314.83, mainly due to inventory write-downs by subsidiaries[13] - The company reported a 129.90% increase in non-operating income to RMB 8,333,426.65 from RMB 3,624,863.06, primarily from increased government subsidies[13]